Clinical Trials Logo

Filter by:
NCT ID: NCT06400121 Not yet recruiting - Depression Clinical Trials

Apimostinel + Automated Neurocognitive Training for Depression

Start date: September 1, 2024
Phase: Phase 2
Study type: Interventional

Apimostinel shows initial promise as a novel rapid-acting antidepressant medication with minimal side effects or safety concerns. Cognitive Training (CT) is a digital intervention that has shown promise in extending the durability of another similar drug (ketamine). This randomized controlled trial will test the efficacy and safety of apimostinel (vs. saline) for the acute treatment of depression, and will test the potential of CT to enhance and/or extend the durability of apimostinel's antidepressant effect.

NCT ID: NCT06400095 Recruiting - ARDS Clinical Trials

Ventilatory Parameters in Predicting Outcomes in ARDS Patients

OCTANE
Start date: June 1, 2023
Phase:
Study type: Observational

This is a single-centre prospective observational study aimed to determine if Pocc (occlusion pressure at 100 msec), TCe ( Expiratory time constant ), Mechanical Stress power, Ventilatory ratio and C20/Cdyn would predict outcomes in patients with moderately severe ARDS (Acute respiratory distress syndrome), who are on mechanical ventilation

NCT ID: NCT06400004 Not yet recruiting - Heart Diseases Clinical Trials

Lumason® Infusion vs. Bolus Administrations

Start date: April 30, 2024
Phase: Phase 3
Study type: Interventional

A phase III study designed as a randomized, within-patient comparison of continuous infusion of diluted Lumason® versus the bolus administration of undiluted Lumason® for degree of LVO and assessment of LV EBD (co-primary endpoints).

NCT ID: NCT06399952 Recruiting - Sleep Disorder Clinical Trials

Baker Gordon Syndrome Natural History Study

BAGOS
Start date: April 30, 2024
Phase:
Study type: Observational

The goal of this study is to conduct a prospective, longitudinal assessment of the natural clinical progression of children and adults with Synaptotagmin1-Associated Neurodevelopmental Disorder also known as Baker Gordon Syndrome (BAGOS). This will be performed by acquiring baseline measurements and developing effective outcome measures and diagnostic tools for the disorder, to prepare the healthcare system for future clinical trials.

NCT ID: NCT06399939 Recruiting - Sleep Deprivation Clinical Trials

The Function of Biphasic Sleep in Infants

Start date: September 1, 2023
Phase: N/A
Study type: Interventional

This study is designed to investigate developmental changes in naps and nap function on memory from 9 to 15 months of age. Memory is measured by a task in which the experimenter interacts with a toy and the measure of memory is whether the child imitates that action when given the toy. Sleep is assessed with a watch that detects motion which provides an estimate of sleep and a set of electrodes placed on the head that measures brain activity during sleep. Infants are recruited at 9 months and sleep and memory are measured again 3- and 6-months later. At each visit, memory is tested before and after a nap (either the morning or afternoon nap) and naps are recorded with the sleep electrodes.

NCT ID: NCT06399900 Recruiting - Aging Clinical Trials

ENhancing Exercise With LIGHT to Improve Functioning in PAD

ENLIGHTEN PAD
Start date: June 1, 2024
Phase: N/A
Study type: Interventional

The ENLIGHTEN PAD Trial will collect preliminary data to test whether daily 660 nm light treatment of the lower extremities immediately before home-based walking exercise sessions improves six-minute walk distance at 4-month follow-up, compared to sham light, in people with lower extremity peripheral artery disease (PAD).

NCT ID: NCT06399874 Recruiting - Clinical trials for Nightmares Associated With Chronic Post-Traumatic Stress Disorder

Pilot Trial Comparing Nightmare Deconstruction and Reprocessing vs. NightWare Wristband

NDR/NW
Start date: June 11, 2024
Phase: Phase 2
Study type: Interventional

The overall goal of this Phase IIa randomized controlled pilot trial is to assess the potential efficacy of two emerging treatments for post-trauma nightmares and to test the feasibility of study design and methods. Symptom change will be assessed in two treatment arms: (1) Nightmare Deconstruction and Reprocessing (NDR), an exposure-based psychotherapy; and (2) NightWare (NW), a non-exposure approach using a wristband device. We will also assess the feasibility of circadian-dependent blood sampling and use of another wristband to collect physiologic data. Toward this goal, we will pursue the following specific aims: (1) Compare evidence of how well participants tolerate and comply with the different treatments and to test feasibility of methods and procedures; (2) Collect additional evidence of the potential efficacy of two contrasting non-pharmacologic approaches to treating posttraumatic nightmares; (3) Explore the operational stress index (OSI) as a reliable, objective measure of sleep disturbance and nightmare events.

NCT ID: NCT06399861 Not yet recruiting - Clinical trials for Extremely Premature Infant

Humidity in Incubators for Tiny Infants

HumidITI
Start date: May 1, 2024
Phase: N/A
Study type: Interventional

The objective of the study is to assess 2 different initial incubator humidification protocols for infants <25 weeks' gestation admitted to the neonatal intensive care unit (NICU). The hypothesis is that a higher starting humidity decreases dehydration and results in no difference in survival or morbidity. Higher (90%) and lower (70%) starting humidity will be compared.

NCT ID: NCT06399718 Recruiting - Clinical trials for Masseter Muscle Prominence

A Study to Assess BOTOX Injections for the Change of Masseter Muscle Prominence in Adult Participants

Start date: April 30, 2024
Phase: Phase 3
Study type: Interventional

The masseter muscle is one of the muscles in the lower face used for chewing. The prominence of the masseter muscle can appear as a widened lower face which some individuals deem as aesthetically undesirable and can be treated by selectively weakening the masseter muscles with small quantities of botulinum toxin. The purpose of this study is to assess how safe and effective injection of onabotulinumtoxinA (BOTOX) is in adult participants with Masseter Muscle Prominence (MMP). BOTOX is being investigated for the treatment of Muscle Masseter Prominence. In Period 1, participants are placed in 1 of 2 groups, called treatment arms. Each group receives a different treatment, placebo or BOTOX. There is a 1 in 4 chance that participants will be assigned to placebo. In Period 2, eligible participants can receive an optional open-label retreatment of BOTOX. Approximately 200 adult participants with MMP will be enrolled in the study at approximately 20 sites in the United States. Participants will receive intramuscular injections across both the right and left masseter muscle of either BOTOX or placebo on Day 1. Participants who are eligible for re-treatment will be given a BOTOX injection on either the Day 180, 210, 240, or 270 visit and will be followed up for up to 6 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular monthly visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, checking for side effects, and completing questionnaires.

NCT ID: NCT06399692 Not yet recruiting - Clinical trials for Coronary Artery Disease

REvascularization CHoices Among Under-Represented Groups Evaluation: The RECHARGE Trial - Women

RECHARGE:W
Start date: May 1, 2024
Phase: Phase 3
Study type: Interventional

This is a research study in women to compare the outcomes of two procedures that restore blood flow to the arteries of the heart. In one procedure the blockages are ballooned and then stented with a small wire mesh tube through a small incision in the wrist or the groin. The other procedure is an open-heart operation in which healthy blood vessels from inside the chest, leg, and/or forearm are used to "bypass" the blockages (like a detour). Outcomes will be measured by comparing survival and improvement in quality-of-life.